By Business/Source
Currency:USD
2025/Q1
Stock NameRevenueRatio
Business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic491K100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States5.17M100.00%